Bria-OTS2.0 / BriaCell - LARVOL DELTA

BriaCell Presents Positive Data Demonstrating Survival and Clinical Benefits in Advanced Metastatic Breast Cancer at the 2023 AACR (GlobeNewswire) - "BriaCell has developed Bria-OTS2.0 or Bria-APTC, the next generation (enhanced version) of Bria-OTS™, BriaCell’s off-the-shelf personalized immunotherapy for advanced metastatic breast cancer....As expected, Bria-OTS2.0 was significantly more effective than Bria-OTS™ in activating naïve T-cells, potentially suggesting faster acting mechanisms of action and better potency....The unique mechanism of action allows both direct activation of T-cells, and indirect activation (i.e., by producing immune activating factors) of the immune cells for a more potent and faster acting anti-tumor activity. BriaCell continues to develop Bria-OTS2.0 to enhance the potency of the initial version of Bria-OTS™ which is planned to be used in its upcoming phase I/IIa clinical study."

Clinical • Breast Cancer • Oncology • Solid Tumor